Legend Biotech CEO Ingrid Zhang purchases $163,200 in shares
Legend Biotech Corp (NASDAQ:LEGN) CEO Ingrid Zhang acquired ordinary shares of the company on November 17, 2026, purchasing 20,000 shares at $8.16 per share, which amounts to a total investment of $163,200. This insider purchase is particularly noteworthy given the current stock price of $15.25, close to the 52-week low of $15.14, following a decline of nearly 46% over the past year.
Following the acquisition, Zhang holds a total of 1,151,860 ordinary shares of Legend Biotech Corp. Analysts have deemed the stock undervalued at present, with the company listed on InvestingPro’s Most Undervalued list. For those interested in a more in-depth analysis, the company’s Pro Research Report is available for Legend Biotech and over 1,400 other US equities.
In recent news, Legend Biotech reported its Q3 2026 financial results, which included a revenue of $359.5 million, slightly exceeding Wall Street’s expectations of $358.63 million. However, the earnings per share were a loss of $0.13, considerably missing the forecasted loss of $0.0037. Despite the earnings miss, the company reported a 36% year-over-year increase in CARVYKTI net trade sales, reaching $710 million for the quarter.
Furthermore, Legend Biotech upgraded its fourth-quarter product gross-margin outlook to the high-50% range.
H.C. Wainwright maintained a Buy rating for Legend Biotech, with a price target of $65.00. The firm highlighted the company’s advancements in reaching half of the U.S. Carvykti apheresis for second- and third-line patients. These developments suggest a mixed financial performance, but also point towards potential growth areas for the company.
Rewritten by urgent.news; may contain errors — check the original.
